Global Pediatric Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type, by Technology, by Indication : Global Opportunity Analysis and Industry Forecast, 2022-2031

Global Pediatric Vaccine Market Research, 2031

The global pediatric vaccine market size was valued at $21.4 billion in 2021, and is projected to reach $36.4 billion by 2031, growing at a CAGR of 5.4% from 2022 to 2031. Pediatric vaccines are products that are usually given in childhood to protect against serious, often deadly diseases. By stimulating your body’s natural defenses, they prepare your body to fight the disease faster and more effectively. Furthermore, pediatric vaccines help children immune system fight infections more efficiently by sparking their immune response to specific diseases. Then, if the virus or bacteria ever invades their body in the future, their immune system will already know how to fight it. These vaccines are very safe. All vaccines go through rigorous safety testing, including clinical trials, before they are approved for the public. Countries will only register and distribute vaccines that meet rigorous quality and safety standards.

Increase in demand for pediatric vaccine market size is anticipated to increase globally during the pediatric vaccine market forecast period , owing to increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines and rise in uptake of new vaccine. In addition, favorable reimbursement and increasing government support further drive the pediatric vaccine market growth globally. However, rising cost of vaccines, low accessibility to remote areas and increasing availability of biosimilars at low rates restrain the pediatric vaccine industry growth. Conversely, rise in demand in emerging markets and increase in R&D activities to develop new vaccines are expected to offer lucrative pediatric vaccine market opportunity for the key players in the market.

The global pediatric vaccine market size is segmented on the basis of type, technology, indication and region. On the basis of type, the market is bifurcated into monovalent and multivalent. On the basis of technology, the market is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. On the basis of indication, the market is classified into varicella, diphtheria, pertussis and tetanus, influenza, human papilloma virus, measles, mumps and rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, other indications. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Global pediatric vaccine market by type

By type, the monovalent segment was the major revenue contributor of pediatric vaccine market share in 2021, and is anticipated to continue this trend during the forecast period, owing to safety and stability associated with such vaccines coupled with the ability to develop a prompt immune response. In addition, increase in awareness regarding vaccination program, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries and rise in research and development activities to develop vaccine further boost the market growth. On the other side, multivalent segment is projected to exhibit the fastest market growth during the forecast period, owing to an increase in the prevalence of infectious diseases in children and the focus of major players on developing hexavalent, tetravalent, and pentavalent vaccines further boost growth of the pediatric vaccine industry.

Global pediatric vaccine market by technology

By technology, the subunit, recombinant, polysaccharide, and conjugate vaccines segment was the major revenue contributor of pediatric vaccine market share in 2021, and is anticipated to continue this trend during the forecast period, owing to these vaccines are considered to be the most efficient alternative to traditional vaccines in the prevention of various human diseases. In addition, the increase in number of regulatory clearances are expected to fuel the subunit, recombinant, polysaccharide, and conjugate vaccines segment growth during the forecast period. Furthermore, various key players have been actively researching on polysaccharide vaccine for expanding its indicated use for pediatric age group.

Global pediatric vaccine market by indication

By indication, the pneumococcal disease segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the pediatric vaccine market forecast, owing to introduction of novel pneumococcal vaccines in the pediatric vaccine industry and rise in awareness among patients regarding pneumococcal vaccines. In addition, several initiatives taken by governments such as various immunization programs for pneumonia have supported the expansion of global pneumococcal vaccines market. Moreover, initiatives taken by WHO such as the Global Action Plan for pneumonia pertaining to reduction of mortality from pneumonia has propelled the market growth. Further, giant strides taken in the direction of developing new pneumococcal vaccines have catalyzed the market growth.

Global pediatric vaccine market by region

By region, North America dominated the market in 2021, accounting for the highest  market share, and is anticipated to maintain this trend during the forecast period. Some of the key factors that can be attributed to its dominance are an increase in R&D investments by numerous companies and a rise in government support for immunization and the development of pediatric vaccines. In addition, the presence of advanced healthcare infrastructure, increase in pediatric population and facilities for immunization supports the growth of this segment.

The major companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global pediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global pediatric vaccine market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global pediatric vaccine market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global  pediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.

  Global Pediatric Vaccines Market Report Highlights

Aspects	Details
Market Size By 2031	USD 36.4 billion
Growth Rate	CAGR of 5.4%
Forecast period	2021 - 2031
Report Pages	310
By Type	Monovalent Multivalent
By Technology	Live Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
By Indication	Varicella Human Papilloma Virus Measles, Mumps and Rubella Meningococcal Disease Pneumococcal Disease Polio Rotavirus Diphtheria, Pertussis and Tetanus Influenza Other Indications
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest Of Europe) Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest Of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest Of LAMEA)
Key Market Players	Novavax, Inc., Sanofi Aventis, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Merck & Co., Inc., CSL Limited, Pfizer Inc., Emergent BioSolutions Inc., AstraZeneca Plc., Johnson & Johnson

Analyst Review

This section provides opinions of the CXOs of key companies operating in the pediatric vaccine market. According to the CXOs, the adoption of pediatric vaccines is expected to increase due to rise in the prevalence of infectious disease and growth in demand for vaccines. As per the CXOs, vaccines are anticipated to witness high adoption in the near future, owing to growth in number of immunization programs across the globe. In addition, the market exhibits high growth rate, owing to surge in awareness about use of the pediatric vaccine.

By region, North America is expected to remain dominant during the forecast period, due to local presence of large in-house vaccine manufacturers such as GSK, Merck & Co., Inc., and Pfizer. Moreover, Asia-Pacific registered highest CAGR and is expected to continue this trend throughout the forecast period, owing to improvement in healthcare facilities, rise in disposable income, surge in adoption of vaccination awareness programs, and rapid improvement in economic conditions.

Author Name(s) : Pradnya Kote| Madhuvanti Balkrishna Divekar | Roshan Deshmukh

Related Tags

• Drug Delivery
• Protein Therapeutics
• Infectious Diseases